Greenwich LifeSciences' CEO on Advancing HER2+ Immunotherapy | Phase III Insights & Strategy
Jun. 24, 2025
Greenwich LifeSciences (Nasdaq: GLSI) is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu (human epidermal growth factor receptor 2) protein, a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or “over-expressor”) levels.
Greenwich LifeSciences is a client of RedChip. Visit RedChip.com/stocks/GLSI to learn more.
